Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With LABA Safety Under Fire, Novartis Addresses Post-Market Studies

Executive Summary

Novartis AG is evaluating how to move forward with FDA's extensive new post-marketing safety requirements for long-acting beta agonists as part of its ongoing review of the safety of their use in asthma.

You may also be interested in...



Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame

Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.

Novartis Cuts 2,000 Jobs In Switzerland And U.S., Pricing Pressures To Blame

Novartis intends to improve productivity and absorb pricing pressures by closing two Swiss manufacturing facilities and transferring some research to the U.S.

FDA Supersizes Its Order For LABA Safety Studies

The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS053338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel